Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 20

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 20
---
 U.S. Holder should consult its own tax advisor with respect to the particular tax consequences of the Corporate Mergers to such holder, including the consequences of receiving any particular mix of Clearwater Common Stock and cash Merger Consideration. Each Enfusion Stockholder should review the section titled “The Transactions—Material U.S. Federal Income Tax Consequences of the Corporate Mergers,” which describes the anticipated material U.S. federal income tax consequences (including U.S. federal withholding tax consequences) of the Corporate Mergers to certain Enfusion Stockholders. The U.S. federal income tax consequences of the LLC Merger are not addressed herein, and each member of Enfusion OpCo should consult with its own tax advisor regarding the consequences thereof.

| Q: | When are the Transactions expected to be completed? |

| A: | Clearwater and Enfusion currently expect the Transactions to be completed during the second quarter of 2025,                                                                                                                                            
 subject to the affirmative vote of the holders of at least a majority of the outstanding shares of Enfusion Common Stock and Enfusion Class B Common Stock in favor of adoption of the Merger Agreement, the expiration or termination of the           
 waiting period (and any extensions thereof) applicable to the Transactions under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), and the satisfaction or waiver of the other conditions to Closing                
 contained in the Merger Agreement. However, Clearwater and Enfusion cannot predict the actual date on which the Transactions will be completed because completion is subject to conditions beyond their control and it is possible that such conditions 
 could result in the Transactions being completed earlier or later or not being completed at all. See the sections titled “The Transactions—Regulatory Clearances and Approvals” and “The Merger Agreement—Conditions to the                             
 Transactions.”                                                                                                                                                                                                                                          |

| Q: | What am I being asked to vote on? |

| A: | You are being asked to vote upon the following proposals: |

| 1. | Proposal 1—The Merger Agreement Proposal: the proposal to adopt the Merger Agreement, which                                                                                                                      
 is further described in the sections titled “The Transactions” and “The Merger Agreement” and a copy of which is attached to this Proxy Statement/Prospectus as Annex A, and to approve the Mergers (the “Merger 
 Agreement Proposal”); and                                                                                                                                                                                        |

| 2. | Proposal 2—The Adjournment Proposal: